



Searing Point
Chartered Accountants

Company Number: 329822

Lynch Medical Supplies (LMS) Limited
Annual Report and Financial Statements
for the financial year ended 31 December 2024

Searing Point Chartered Accountants
Statutory Auditors
Frankfort Building
Dundrum Road
Dundrum
D14 RX27

Lynch Medical Supplies (LMS) Limited
CONTENTS

	Page
Directors and Other Information	3
Directors' Report	4 - 5
Directors' Responsibilities Statement	6
Independent Auditor's Report	7 - 8
Appendix to the Independent Auditor's Report	9
Profit and Loss Account	10
Balance Sheet	11
Statement of Changes in Equity	12
Statement of Cash Flows	13
Notes to the Financial Statements	14 - 19
Supplementary Information on Trading Statement	21

Lynch Medical Supplies (LMS) Limited
DIRECTORS AND OTHER INFORMATION

Directors	John Lynch Lara Lynch
Company Secretary	John Lynch
Company Number	329822
Registered Office and Business Address	Unit C3, M1 Business Park Balbriggan Dublin K32X318 Ireland
Auditors	Searing Point Chartered Accountants Frankfort Building Dundrum Road Dundrum D14 RX27
Bankers	Bank of Ireland 88-90 Lower Camden Street Dublin 2 D02 PY23
Solicitors	McCann Fitzgerald Riverside One Sir John Rogerson's Quay Grand Canal Dock Dublin 2

Lynch Medical Supplies (LMS) Limited

DIRECTORS' REPORT

for the financial year ended 31 December 2024

The directors present their report and the audited financial statements for the financial year ended 31 December 2024.

Principal Activity and Review of the Business

The principal activity of the Company is the supply of medical and surgical equipment and orthopaedic appliances.

There has been no significant change in these activities during the financial year ended 31 December 2024.

Results and Dividends

The profit for the financial year after providing for depreciation and taxation amounted to €2,134,044 (2023 - €2,830,151).

The directors do not recommend payment of a dividend.

At the end of the financial year, the company has assets of €17,685,119 (2023 - €15,528,116) and liabilities of €2,603,864 (2023 - €2,580,905). The net assets of the company have increased by €2,134,044.

Directors and Secretary

The directors who served throughout the financial year were as follows:

John Lynch
Lara Lynch

The secretary who served throughout the financial year was John Lynch.

The directors' and the secretary's interests in the shares of the company are as follows:

Name	Class of Shares	Number Held At 31/12/24	Number Held At 01/01/24
John Lynch	Ordinary	1	1
Lara Lynch	Ordinary	1	1
		<u>2</u>	<u>2</u>

There were no changes in shareholdings between 31 December 2024 and the date of signing the financial statements.

In accordance with the Constitution, the directors retire by rotation and, being eligible, offer themselves for re-election.

Future Developments

The company plans to continue its present activities and current trading levels. Employees are kept as fully informed as practicable about developments within the business.

Post Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

Auditors

The auditors, Searing Point Chartered Accountants, continue in office in accordance with section 383(2) of the Companies Act 2014.

Taxation Status

The company is a close company within the meaning of the Taxes Consolidation Act, 1997.

Lynch Medical Supplies (LMS) Limited
DIRECTORS' REPORT

for the financial year ended 31 December 2024

Accounting Records

To ensure that adequate accounting records are kept in accordance with sections 281 to 285 of the Companies Act 2014, the directors have employed appropriately qualified accounting personnel and have maintained appropriate computerised accounting systems. The accounting records are located at the company's office at Unit C3, , M1 Business Park, Balbriggan, Dublin, K32X318.

Signed on behalf of the board



Jofin Lynch
Director

17 December 2025



Lara Lynch
Director

17 December 2025

Lynch Medical Supplies (LMS) Limited
DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 31 December 2024

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.


Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014 and enable the financial statements to be readily and properly audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board



John Lynch
Director

17 December 2025



Lara Lynch
Director

17 December 2025

INDEPENDENT AUDITOR'S REPORT

to the Shareholders of Lynch Medical Supplies (LMS) Limited

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Lynch Medical Supplies (LMS) Limited ('the company') for the financial year ended 31 December 2024 which comprise the Profit and Loss Account, the Balance Sheet, the Statement of Changes in Equity, the Statement of Cash Flows and the related notes to the financial statements, including the summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued in the United Kingdom by the Financial Reporting Council.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2024 and of its profit for the financial year then ended;
- have been properly prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland"; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2014

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

INDEPENDENT AUDITOR'S REPORT

to the Shareholders of Lynch Medical Supplies (LMS) Limited

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the Company. We have nothing to report in this regard.

Respective responsibilities

Responsibilities of directors for the financial statements

As explained more fully in the Directors' Responsibilities Statement set out on page 6, the directors are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, if applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operation, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is contained in the appendix to this report, located at page 9, which is to be read as an integral part of our report.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's shareholders, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's shareholders those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume any responsibility to anyone other than the company and the company's shareholders, as a body, for our audit work, for this report, or for the opinions we have formed.



Patrick Thorpe
for and on behalf of
SEARING POINT CHARTERED ACCOUNTANTS
Statutory Auditors
Frankfort Building
Dundrum Road
Dundrum
D14 RX27

17 December 2025

Lynch Medical Supplies (LMS) Limited

APPENDIX TO THE INDEPENDENT AUDITOR'S REPORT

Further information regarding the scope of our responsibilities as auditor

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Lynch Medical Supplies (LMS) Limited
PROFIT AND LOSS ACCOUNT
for the financial year ended 31 December 2024

	Notes	2024 €	2023 €
Turnover	3	18,481,884	16,097,712
Cost of sales		<u>(9,956,490)</u>	<u>(8,550,545)</u>
Gross profit		8,525,394	7,547,167
Administrative expenses		<u>(5,575,284)</u>	<u>(4,709,649)</u>
Operating profit	4	2,950,110	2,837,518
Exceptional items	5	<u>(278,597)</u>	340,431
Profit before interest		2,671,513	3,177,949
Interest payable and similar expenses	6	<u>(211,024)</u>	14,702
Profit before taxation		2,460,489	3,192,651
Tax on profit	8	<u>(326,445)</u>	<u>(362,500)</u>
Profit for the financial year		<u>2,134,044</u>	<u>2,830,151</u>
Total comprehensive income		<u><u>2,134,044</u></u>	<u><u>2,830,151</u></u>

Lynch Medical Supplies (LMS) Limited

BALANCE SHEET


as at 31 December 2024

	Notes	2024 €	2023 €
Fixed Assets			
Tangible assets	9	<u>3,100,315</u>	<u>3,046,937</u>
Current Assets			
Stocks	10	6,170,741	5,967,138
Debtors	11	4,939,638	2,820,891
Cash and cash equivalents		<u>3,474,425</u>	<u>3,693,150</u>
		<u>14,584,804</u>	<u>12,481,179</u>
Creditors: amounts falling due within one year	13	<u>(1,968,331)</u>	<u>(1,882,598)</u>
Net Current Assets		<u>12,616,473</u>	<u>10,598,581</u>
Total Assets less Current Liabilities		<u>15,716,788</u>	<u>13,645,518</u>
Creditors: amounts falling due after more than one year	14	<u>(635,533)</u>	<u>(698,307)</u>
Net Assets		<u>15,081,255</u>	<u>12,947,211</u>
Capital and Reserves			
Called up share capital presented as equity	16	3	3
Retained earnings		<u>15,081,252</u>	<u>12,947,208</u>
Equity attributable to owners of the company		<u>15,081,255</u>	<u>12,947,211</u>

Approved by the board on 17 December 2025 and signed on its behalf by:



John Lynch
Director



Lara Lynch
Director

Lynch Medical Supplies (LMS) Limited
STATEMENT OF CHANGES IN EQUITY
as at 31 December 2024

	Called up share capital €	Retained earnings €	Total €
At 1 January 2023	3	10,117,057	10,117,060
Profit for the financial year	-	2,830,151	2,830,151
At 31 December 2023	3	12,947,208	12,947,211
Profit for the financial year	-	2,134,044	2,134,044
At 31 December 2024	3	15,081,252	15,081,255

Lynch Medical Supplies (LMS) Limited
STATEMENT OF CASH FLOWS
for the financial year ended 31 December 2024

	Notes	2024 €	2023 €
Cash flows from operating activities			
Profit for the financial year		2,134,044	2,830,151
Adjustments for:			
Exceptional items		278,597	(340,431)
Interest payable and similar expenses		211,024	(14,702)
Tax on profit on ordinary activities		326,445	362,500
Depreciation		147,424	70,182
Exceptional items		(278,597)	340,431
		<u>2,818,937</u>	<u>3,248,131</u>
Movements in working capital:			
Movement in stocks		(203,603)	(500,447)
Movement in debtors		(2,118,747)	(389,099)
Movement in creditors		106,190	(155,275)
		<u>602,777</u>	<u>2,203,310</u>
Cash generated from operations		602,777	2,203,310
Interest paid		(211,024)	14,702
Tax paid		(343,364)	-
		<u>48,389</u>	<u>2,218,012</u>
Net cash generated from operating activities		<u>48,389</u>	<u>2,218,012</u>
Cash flows from investing activities			
Payments to acquire tangible assets		(116,449)	(568,106)
		<u>(116,449)</u>	<u>(568,106)</u>
Cash flows from financing activities			
New long term loan		(217,127)	(225,646)
New short term loan		70,000	70,000
Capital element of finance lease contracts		(3,538)	178,538
		<u>(150,665)</u>	<u>22,892</u>
Net cash (used in)/generated from financing activities		<u>(150,665)</u>	<u>22,892</u>
Net (decrease)/increase in cash and cash equivalents		<u>(218,725)</u>	<u>1,672,798</u>
Cash and cash equivalents at beginning of financial year		<u>3,693,150</u>	<u>2,020,352</u>
Cash and cash equivalents at end of financial year	12	<u><u>3,474,425</u></u>	<u><u>3,693,150</u></u>

Lynch Medical Supplies (LMS) Limited

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2024

1. General Information

Lynch Medical Supplies (LMS) Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 329822. The registered office of the company is Unit C3., M1 Business Park, Balbriggan, Dublin, K32X318, Ireland which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

A loan to a director has been fully repaid in 2025, it was not separately identified in previous financial statements. The company is rectifying outstanding filings with the Companies Registration Office in this regard

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 31 December 2024 have been prepared on the going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102).

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

The company qualifies as a medium company as defined by section 280F of the Companies Act 2014 in respect of the financial year.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Land and buildings freehold	- 4% Straight line
Motor vehicles	- 25% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Lynch Medical Supplies (LMS) Limited

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2024

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

Exceptional item

Exceptional items are those that the directors' view are required to be separately disclosed by virtue of their size or incidence to enable a full understanding of the company's financial performance.

3. Turnover

The whole of the company's turnover is attributable to its market in Ireland and is derived from the principal activity of

4. Operating profit	2024	2023
	€	€
Operating profit is stated after charging:		
Depreciation of tangible assets	147,424	70,182
	<u> </u>	<u> </u>
5. Exceptional items	2024	2023
	€	€
Other exceptional item 1	(278,597)	340,431
	<u> </u>	<u> </u>

Lynch Medical Supplies (LMS) Limited
NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2024

6. Interest payable and similar expenses	2024	2023
	€	€
On bank loans and overdrafts	<u>211,024</u>	<u>(14,702)</u>

7. Employees and remuneration

Number of employees

The average number of persons employed (including executive directors) during the financial year was as follows:

	2024	2023
	Number	Number
Directors	2	2
Employees	42	42
	<u>44</u>	<u>44</u>

The staff costs (inclusive of directors' salaries) comprise:

	2024	2023
	€	€
Wages and salaries	3,564,325	2,823,744
Social welfare costs	313,528	268,996
Pension costs	573,302	521,876
	<u>4,451,155</u>	<u>3,614,616</u>

8. Tax on profit

	2024	2023
	€	€
(a) Analysis of charge in the financial year		
Current tax:		
Corporation tax at 12.50% (2023 - 12.50%) (Note 8 (b))	<u>326,445</u>	<u>362,500</u>

(b) Factors affecting tax charge for the financial year

The tax assessed for the financial year differs from the standard rate of corporation tax in Ireland 12.50% (2023 - 12.50%). The differences are explained below:

	2024	2023
	€	€
Profit taxable at 12.50%	<u>2,460,489</u>	<u>3,192,651</u>
Profit before tax		
multiplied by the standard rate of corporation tax		
in Ireland at 12.50% (2023 - 12.50%)	307,561	399,081
Effects of:		
Expenses not deductible for tax purposes	456	(45,354)
Depreciation in excess of capital allowances for period	18,428	8,773
	<u>326,445</u>	<u>362,500</u>
Total tax charge for the financial year (Note 8 (a))		

Lynch Medical Supplies (LMS) Limited
NOTES TO THE FINANCIAL STATEMENTS
for the financial year ended 31 December 2024

9. Tangible assets	Land and buildings freehold	Motor vehicles	Total
	€	€	€
Cost			
At 1 January 2024	2,348,762	768,357	3,117,119
Additions	1,552	199,250	200,802
At 31 December 2024	<u>2,350,314</u>	<u>967,607</u>	<u>3,317,921</u>
Depreciation			
At 1 January 2024	-	70,182	70,182
Charge for the financial year	-	147,424	147,424
At 31 December 2024	<u>-</u>	<u>217,606</u>	<u>217,606</u>
Net book value			
At 31 December 2024	<u><u>2,350,314</u></u>	<u><u>750,001</u></u>	<u><u>3,100,315</u></u>
At 31 December 2023	<u><u>2,348,762</u></u>	<u><u>698,175</u></u>	<u><u>3,046,937</u></u>
10. Stocks		2024	2023
		€	€
Finished goods and goods for resale		<u><u>6,170,741</u></u>	<u><u>5,967,138</u></u>
The replacement cost of stock did not differ significantly from the figures shown.			
11. Debtors		2024	2023
		€	€
Trade debtors		2,805,335	2,219,167
Directors' current accounts		2,034,303	591,724
Prepayments		100,000	10,000
		<u><u>4,939,638</u></u>	<u><u>2,820,891</u></u>
12. Cash and cash equivalents		2024	2023
		€	€
Cash and bank balances		<u><u>3,474,425</u></u>	<u><u>3,693,150</u></u>
13. Creditors		2024	2023
Amounts falling due within one year		€	€
Amounts owed to credit institutions		70,000	70,000
Net obligations under finance leases and hire purchase contracts		175,000	178,538
Trade creditors		750,410	968,799
Taxation (Note 15)		778,156	639,729
Other creditors		(34,104)	15,532
Accruals		228,869	10,000
		<u><u>1,968,331</u></u>	<u><u>1,882,598</u></u>

Lynch Medical Supplies (LMS) Limited
NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2024

14. Creditors			2024	2023
Amounts falling due after more than one year			€	€
Bank loan			551,180	698,307
Finance leases and hire purchase contracts			84,353	-
			<u>635,533</u>	<u>698,307</u>
Loans				
Repayable in one year or less, or on demand (Note 13)			70,000	70,000
Repayable between two and five years			551,180	698,307
			<u>621,180</u>	<u>768,307</u>
Net obligations under finance leases and hire purchase contracts				
Repayable within one year			175,000	178,538
Repayable between one and five years			84,353	-
			<u>259,353</u>	<u>178,538</u>
15. Taxation			2024	2023
			€	€
Creditors:				
VAT			289,291	267,515
Corporation tax			176,445	193,364
PAYE			312,420	178,850
			<u>778,156</u>	<u>639,729</u>
16. Share capital			2024	2023
			€	€
Description	Number of shares	Value of units		
Allotted, called up and fully paid				
Ordinary	2	€1.27 each	<u>3</u>	<u>3</u>
17. Capital commitments				
The company had no material capital commitments at the financial year-ended 31 December 2024.				
18. Directors' remuneration			2024	2023
			€	€
Remuneration			797,024	389,394
Pension contributions			456,000	427,604
			<u>1,253,024</u>	<u>816,998</u>
19. Post-Balance Sheet Events				
There have been no significant events affecting the company since the financial year-end.				

Lynch Medical Supplies (LMS) Limited
NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 31 December 2024

20	Reconciliation of Net Cash Flow to Movement in Net Debt			
	Opening balance	Cash flows	Other changes	Closing balance
	€	€	€	€
Long-term borrowings	(768,307)	217,127	-	(551,180)
Short-term borrowings	-	(70,000)	-	(70,000)
Finance lease and hire purchase	(178,538)	3,538	(84,353)	(259,353)
Total liabilities from financing activities	<u>(946,845)</u>	<u>150,665</u>	<u>(84,353)</u>	<u>(880,533)</u>
Total Cash and cash equivalents (Note 12)				<u>3,474,425</u>
Total net cash				<u>2,593,892</u>

21. Restatement of Comparative Figures

The comparative figures for the financial year ended 31 December 2023 have been restated. The restatement arose due to updates made to the prior-year financial statements during the preparation of the 2024 accounts. These updates were reflected in the opening balances for the current year. The restatement has no impact on the company's current-year financial performance or financial position.

22. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 17 December 2025.